-
Salmon Calcitonin
- indication:For the treatment of post-menopausal osteoporosis
- pharmacologypharmacology:
- mechanism: Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
- toxicity: Salmon calcitonin is devoid of embryotoxic, teratogenic and mutagenic potential.
- absorprion: Salmon calcitonin is rapidly absorbed and eliminated. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively).
- halflife: 50-80 minutes
- roouteelimination: Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.
- volumedistribution:
- clearance: